MCM
INO icon

MAI Capital Management’s Inovio Pharmaceuticals INO Stock Holding History

MAI Capital Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-830
Closed -$1.45K – 3368
2026
Q1 		$1.45K Hold
830
– – ﹤0.01% 4046
2025
Q4 		$1.45K Sell
830
-99
-11% -$218 ﹤0.01% 3520
2025
Q3 		$2.17K Hold
929
– – ﹤0.01% 3292
2025
Q2 		$1.89K Hold
929
– – ﹤0.01% 3444
2025
Q1 		$1.51K Sell
929
-29
-3% -$58 ﹤0.01% 3027
2024
Q4 		$1.75K Buy
+958
New +$4.24K ﹤0.01% 3054

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

MAI Capital Management's INO Position: Q2 2026 in Review

MAI Capital Management sold out of Inovio Pharmaceuticals (INO) in Q2 2026, closing a stake of 830 shares — an estimated $1.45K sold.

MAI Capital Management first reported a position in INO in Q4 2024 and held it in 6 quarters. The position peaked at $2.17K in Q3 2025. 103 funds tracked by Wall St. Rank hold INO as of Q2 2026.

  • MAI Capital Management reported no remaining Inovio Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 830 Inovio Pharmaceuticals shares in Q2 2026, an estimated $1.45K.
  • MAI Capital Management first reported a position in Inovio Pharmaceuticals in Q4 2024 and held it in 6 quarters.
  • MAI Capital Management's Inovio Pharmaceuticals position peaked at $2.17K in Q3 2025.
  • 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.